China News Zone
Tools
Typography

Researchers are conducting phase-1 and phase-2 clinical trials on a China-made inhaled COVID-19 vaccine, a Chinese health official said Friday.

After completing the collection of clinical-trial data, experts will study the safety and effectiveness of the inhaled vaccine, a modified version of an injectable adenovirus vector COVID-19 vaccine that has already hit the market, said Shao Yiming, a researcher at the Chinese Center for Disease Control and Prevention, at a press conference.

The inhaled COVID-19 vaccine was jointly-developed by researchers from the Institute of Military Medicine under the Academy of Military Sciences and China's CanSino Biologics Inc.

Inhaled or nasal-spray vaccines were selected as one of China's vaccine technologies to combat COVID-19 from the very beginning, Shao added.

Another nasal-spray COVID-19 vaccine, developed by Xiamen University, the University of Hong Kong and Beijing Wantai Biological Pharmacy, has completed phase-1 and phase-2 trials. Researchers are applying phase-3 clinical trials overseas, to further evaluate the efficacy of the vaccine, according to Shao. 

This page is provided in cooperation with People's Daily Online.
HELSINKI TIMES does not exercise editorial control over this section and is not responsible for the topics and content of this section.

More News About China

Partners